According to our latest research study on “Generic Injectables Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product Type, Container Type, Application, and Route of Administration,” the generic injectables market size is projected to reach US$ 150.65 billion by 2028 from US$ 74.74 billion in 2021; it is estimated to grow at a CAGR of 10.5% from 2021 to 2028. The report highlights trends prevailing in the market and factors governing the growth of the market.
Generic injectables are counterparts of branded injectables that are not protected by drug patents. They are as effective and safe as the innovator drugs since they have equivalent quality, active ingredients, strength, dosage, form, etc. The R&D cycle of generic injectables is shorter and cheaper. Generic injectable manufacturers do not require much investment in R&D and clinical trials. The generic injectables market growth is attributed to low R&D, marketing, and manufacturing costs, and the rising prevalence of chronic illness cases are expected to drive the growth of the market. However, critical inspection systems for prefilled injection and supply chain- related challenges may hinder the growth of market growth.
Increasing Patent Expiry of Branded Injectables Creating Opportunities for Generic Injectables Market Players:
The patents of branded injectables in several regions are likely to expire in the upcoming years, offering numerous remunerative opportunities to the generic injectables manufacturers. As per a recent publication by Business Standard, patented drugs worth US$ 240 billion will lose patents globally over the coming years. In India, the shortage of branded medicines and the expiry of branded drug patents have prompted generic injectable’s manufacturers to introduce advanced drug delivery systems, including self-injection devices. Biological E Limited, an Indian biotechnology and biopharmaceutical company based in Hyderabad, Telangana, is gaining recognition for broadening its portfolio with the addition of 20 routine and injectable products. Thus, generic injectables companies are tapping regulated markets and exploring other markets to generate incomes and establish stable revenue streams. Additionally, manufacturers in the generic injectables market are becoming future-ready by maintaining adequate supply chains to prevent vulnerabilities, such as those caused by the COVID-19 outbreak. Zydus Cadila is significantly reducing the price of its generic version of Remdesivir, namely Remdac. Thus, the nearing expiry of patent validity of branded injectables is likely to provide significant opportunities to generic injectables manufacturers.
Product Type-Based Insights
The generic injectables market, based on product type, has been bifurcated into large molecule injectables and small molecule injectables. The large molecule injectable segment held a larger share of the market in 2021. However, the small molecule injectable segment is expected to register a higher CAGR in the generic injectables market during 2021–2028.
Container Type-Based Insights
The generic injectables market, based on container type, is segmented into vials, premix, prefilled syringes, ampoules, and others. The vials segment held the largest generic injectables market share in 2021 and is anticipated to continue to be the largest shareholder in 2028.
The generic injectables market, by application, is segmented into oncology, infectious diseases, cardiology, diabetes, immunology, and others. In 2021, the oncology segment held the largest generic injectables market share. However, the generic injectables market for the diabetes segment is expected to grow at the fastest CAGR during 2021–2028.
Route of Administration-Based Insights
The generic injectables market, by the route of administration, is segmented into intravenous, intramuscular, subcutaneous, and others. In 2021, the intravenous segment held the largest share of the market. However, the intramuscular segment is expected to register the highest CAGR in the generic injectables market from 2021 to 2028.
AstraZeneca; Baxter International Inc.; Biocon; Fresenius SE & Co. KGaA; GlaxoSmithKline plc; Hikma Pharmaceuticals PLC; Johnson and Johnson Services, Inc.; Lupin; Merck & Co., Inc.; Viatris Inc.; and Pfizer Inc. are among the leading companies operating in generic injectables market.
The Report Segments Generic Injectables Market as Follows:
Based on product type, generic injectables market is bifurcated into large molecule injectables and small molecule injectables. The generic injectables market, by container type, is segmented into vials, premix, prefilled syringes, ampoules, and others. Based on application, the market is segmented into oncology, infectious diseases, cardiology, diabetes, immunology, and others. By the route of administration, the generic injectables market is segmented into intravenous, intramuscular, subcutaneous, and others. Based on geography, the market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South & Central America (Brazil, Argentina, and the Rest of SCAM).
TIP is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Ankit Mathur
E-mail: [email protected]